Document is current
Any future updates will be listed below
-
Authors
Pomrenze, Matthew B. https://orcid.org/0000-0002-9032-5911
Vaillancourt, Sam
Salgado, Juliana S. https://orcid.org/0000-0002-3687-846X
Raymond, Kendall B.
Llorach, Pierre
Sacai, Hiroaki
Rijsketic, Daniel Ryskamp https://orcid.org/0000-0002-2197-0730
Hietamies, Tuuli M.
Touponse, Gavin C. https://orcid.org/0000-0001-8087-3351
Cardozo Pinto, Daniel F. https://orcid.org/0000-0002-6104-4643
Rastegar, Zahra
Casey, Austen B. https://orcid.org/0000-0002-4670-851X
Eshel, Neir https://orcid.org/0000-0002-5976-2013
Malenka, Robert C. https://orcid.org/0000-0002-5428-5211
Heifets, Boris D. https://orcid.org/0000-0003-1474-0379
-
Funding
Funding for this research was provided by:
U.S. Department of Health & Human Services | NIH | National Institute of Mental Health (MH130591, MH110610, MH123791)
U.S. Department of Health & Human Services | NIH | National Institute on Drug Abuse (DA042012, DA056573, DA042012)
Burroughs Wellcome Fund
Simons Foundation Bridge to Independence Award
- License Information
-
More Information
Article History
Received: 14 October 2024
Revised: 20 June 2025
Accepted: 14 July 2025
First Online: 24 July 2025
Competing interests
: H.S. is an employee of Daiichi Sankyo. D.R.R. is an employee of Tensor Analytics, LLC. B.D.H. is on the scientific advisory boards of Journey Clinical and Osmind, and is a paid consultant to Arcadia Medicine, Inc, Tactogen, LLC, and Vida Ventures, LLC. N.E. is a paid consultant for Boehringer Ingelheim. R.C.M. is now on leave from Stanford, functioning as Chief Scientific Officer at Bayshore Global Management. R.C.M. is on the scientific advisory boards of MapLight Therapeutics, Bright Minds, MindMed, and Aelis Farma.
